MedWatch

Copenhagen lands top three spot in global pharmaceutical ranking

The Danish capital area is one of the world's leading regions within the life science industry, according to investment bank Torreya. CEO at the Danish Chamber of Commerce calls it "simply excellent."

Photo: Novo Nordisk / PR

Greater Copenhagen moves into the top three of pharmaceutical industries in the world, according to a ranking made by global investment banking boutique Torreya.

Only the regions New York in the US and Basel in Switzerland surpass Copenhagen, landing in first and second places, respectively.

The past year, New York, Basel and Tokyo have receded, allowing for Copenhagen to surge due to the "outstanding performance of Novo Nordisk," the report states. Strong performances from Boston, Indiana and Cambridge with firms Moderna, Eli Lilly and Astrazeneca, respectively, are also cited to explain the change in ranking.

The report concludes that "the pharmaceutical industry continues to be remarkably concentrated by region."

The four top-ranking regions within the industry account for 29 percent of the sector's total value.

CEO at the Danish Chamber of Commerce Brian Mikkelsen is pleased to see Copenhagen's advancement.

"It's quite simply excellent that the Danish capital region is in third place on the list of the most valuable regions. Denmark is a life science nation, and this is emphasized by this fine placement. We should be proud of our life science industry," Mikkelsen says in a written comment to MedWatch.

He urges that the position isn't taken for granted.

"A lot of countries work very hard to offer the most optimal framework for life science firms. That's why it's crucial that we continue to optimize the Danish framework conditions so we can enjoy the massive societal contributions from the life science industry," Mikkelsen says.

Stockholm wants to become leading life science region

Column: The EU pharma strategy must become more ambitious

Life science firms warm up before Tour de France starts in Denmark

Novo Nordisk wins big on strong US dollar 

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs